Form 4: IDEXX Laboratories EVP, CFO and Treasurer Brian P. McKeon Reports Stock Transactions
SEC Form 4 Filing
Brian P. McKeon, EVP, CFO and Treasurer of IDEXX Laboratories, reports transactions involving common stock and restricted stock units on February 14, 2025.
Summary
- On February 14, 2025, Brian P. McKeon, the EVP, CFO, and Treasurer of IDEXX Laboratories, executed transactions involving the company's common stock and restricted stock units (RSUs).
- McKeon acquired shares through the vesting of RSUs, specifically 252, 303, 308, and 299 shares from different RSU grants.
- These RSUs vested in annual installments starting on February 14 of 2022, 2023, 2024 and 2025 respectively.
- He also disposed of 569 shares to cover tax obligations at a price of $444.53 per share.
- Following these transactions, McKeon directly owns 31,549.5926 shares of common stock and indirectly owns 18,050 shares through Estony McKeon Family, LLC.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing represents routine transactions related to executive compensation and tax obligations.
Industry Context
Form 4 filings are standard disclosures required by the SEC to ensure transparency regarding insider transactions, allowing investors to stay informed about the actions of company executives.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in financial analysis to gauge executive sentiment and potential future performance.
- Comparing McKeon's transactions to those of executives at similar companies like Zoetis (ZTS) or VCA Animal Hospitals (owned by Mars, Inc.) can provide context, although direct comparisons are limited due to variations in compensation structures and individual financial strategies.
- Generally, consistent patterns of stock purchases by executives are viewed positively, while frequent sales may raise concerns, although sales to cover tax obligations are common and usually not a cause for alarm.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are part of standard executive compensation practices.
- Shareholders can use this information to monitor insider activity, but the reported transactions are unlikely to significantly influence the company's performance or stock price.
Key Dates
| Date | Description |
|---|---|
| 02/14/2022 | First vesting date of 252 Restricted Stock Units. |
| 02/14/2023 | First vesting date of 303 Restricted Stock Units. |
| 02/14/2024 | First vesting date of 308 Restricted Stock Units. |
| 09/30/2024 | Date of purchase of shares under the Issuer's Employee Stock Purchase Plan. |
| 12/31/2024 | Date of purchase of shares under the Issuer's Employee Stock Purchase Plan. |
| 02/14/2025 | Date of transactions: vesting of RSUs and disposal of shares for tax obligations; First vesting date of 299 Restricted Stock Units. |
| 02/18/2025 | Date of Form 4 filing. |
Keywords
IDEXX Laboratories, Brian P. McKeon, Form 4, Stock Transactions, Restricted Stock Units, Insider Trading, EVP, CFO, Treasurer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.